Ibrutinib M25
CAS: 1839090-60-6
Rif. 3D-PYC09060
| 1mg | Fuori produzione | ||
| 5mg | Fuori produzione | ||
| 10mg | Fuori produzione | ||
| 25mg | Fuori produzione | ||
| 50mg | Fuori produzione |
Informazioni sul prodotto
Ibrutinib is a small molecule drug that inhibits Bruton's tyrosine kinase (BTK) and has been shown to be effective against chronic lymphocytic leukemia. BTK is a receptor tyrosine-kinase enzyme that plays an important role in the regulation of B-cell proliferation, differentiation, and apoptosis. Ibrutinib binds to BTK and blocks the activation of downstream signaling pathways, which leads to inhibition of cell division. Ibrutinib also inhibits the phosphorylation of peptides, including FcepsilonRIgA and FcepsilonRIgD; this inhibition leads to suppression of cell proliferation. Ibrutinib M25 is a high purity product with a purity level greater than 98%. It is an ionizable compound with CAS No. 1839090-60-6. As such, it can be used as a research tool for studies involving cellular biology or receptor binding studies.
